Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour mutational burden: an overview for pathologists.

Pathology - 1 Apr 2022

Doig Kenneth D, Fellowes Andrew, Scott Prudence, Fox Stephen B

Abstract excerpt

Cancer immunotherapy holds great promise and has shown durable responses in many patients; however, these responses are not uniform in all patients or all tumour streams. There is an ongoing clinical need for objective diagnostic biomarkers to identify patients that will respond to immunotherapies. Tumour mutational burden (TMB) is a diagnostic biomarker that can stratify cancer patients for response to immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Immunotherapy and Immune Responses

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 35153070
DOI: 10.1016/j.pathol.2021.11.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour mutational burden: an overview for pathologists.PMID 35153070Read ↗

Tumour mutational burden: clinical utility, challenges and emerging improvements.Semantic proximity Read ↗

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Semantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Methods of measurement for tumor mutational burden in tumor tissueSemantic proximity Read ↗

Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.Semantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.